- Supplementary figure 1: Iba1/AIF1 expression separates MBM[supplements/297080_file08.pdf]
- Supplementary figure 2: The indicators of favorable disease course ITGB7, SUSD3 and APBB1IP are broadly expressed among immune cell subsets[supplements/297080_file09.pdf]
- Supplementary figure 3: Methylome profiling uncovered epigenetic regulatory sites in the ITGB7 gene[supplements/297080_file10.pdf]
- Supplementary figure 4: Single sample GSEA revealed classification of immune molecular subtypes of MBM[supplements/297080_file11.pdf]
- Supplementary figure 5: MET-FISH analysis revealed absence of MET receptor amplifications in MBM[supplements/297080_file12.pdf]
- Supplementary figure 6: Expression of interferon-related genes is enriched in MBM of ITGB7high/IScorehigh phenotype[supplements/297080_file13.pdf]
- Supplementary figure 7: The mTOR/pS6 signaling is activated in MBM[supplements/297080_file14.pdf]
Posted October 16, 2023.
MET receptor activation by stromal cells serves as promising target in melanoma brain metastases
